Chemical Compound Review:
Cilengitide 2-[(2S,5R,8S,11S)-5-benzyl- 11-[3...
Synonyms:
SureCN34082, CHEMBL429876, SureCN451423, AG-E-37840, EMD-12192, ...
Smith,
Friess,
Langrehr,
Oettle,
Raedle,
Niedergethmann,
Dittrich,
Hossfeld,
St??ger,
Neyns,
Herzog,
Piedbois,
Dobrowolski,
Scheithauer,
Hawkins,
Katz,
Balcke,
Vermorken,
van Belle,
Davidson,
Esteve,
Castellano,
Kleeff,
Tempia-Caliera,
Kovar,
Nippgen,
Chen,
Park,
Khankaldyyan,
Gonzales-Gomez,
Tohme,
Moats,
Bading,
Laug,
Conti,
Tucker,
- Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Burke, P.A., DeNardo, S.J., Miers, L.A., Lamborn, K.R., Matzku, S., DeNardo, G.L. Cancer Res. (2002)
- alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Taga, T., Suzuki, A., Gonzalez-Gomez, I., Gilles, F.H., Stins, M., Shimada, H., Barsky, L., Weinberg, K.I., Laug, W.E. Int. J. Cancer (2002)
- Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Albert, J.M., Cao, C., Geng, L., Leavitt, L., Hallahan, D.E., Lu, B. Int. J. Radiat. Oncol. Biol. Phys. (2006)
- Integrins: molecular targets in cancer therapy. Tucker, G.C. Current oncology reports. (2006)
- Divalent cations and the relationship between alphaA and betaA domains in integrins. Seow, K.T., Xiong, J.P., Arnaout, M.A., Welge, J., Rippmann, F., Goodman, S.L. Biochem. Pharmacol. (2002)
- Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Beekman, K.W., Colevas, A.D., Cooney, K., Dipaola, R., Dunn, R.L., Gross, M., Keller, E.T., Pienta, K.J., Ryan, C.J., Smith, D., Hussain, M. Clinical genitourinary cancer. (2006)
- Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Chen, X., Park, R., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M., Moats, R.A., Bading, J.R., Laug, W.E., Conti, P.S. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. (2006)
- A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. Friess, H., Langrehr, J.M., Oettle, H., Raedle, J., Niedergethmann, M., Dittrich, C., Hossfeld, D.K., St??ger, H., Neyns, B., Herzog, P., Piedbois, P., Dobrowolski, F., Scheithauer, W., Hawkins, R., Katz, F., Balcke, P., Vermorken, J., van Belle, S., Davidson, N., Esteve, A.A., Castellano, D., Kleeff, J., Tempia-Caliera, A.A., Kovar, A., Nippgen, J. BMC Cancer (2006)
- Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2). Kamm, W., Jonczyk, A., Jung, T., Luckenbach, G., Raddatz, P., Kissel, T. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. (2000)
- Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Yamada, S., Bu, X.Y., Khankaldyyan, V., Gonzales-Gomez, I., McComb, J.G., Laug, W.E. Neurosurgery (2006)
- alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Nisato, R.E., Tille, J.C., Jonczyk, A., Goodman, S.L., Pepper, M.S. Angiogenesis (2003)
- Cilengitide Merck. Smith, J.W. Current opinion in investigational drugs (London, England : 2000) (2003)
- Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Merklinger, S.L., Jones, P.L., Martinez, E.C., Rabinovitch, M. Circulation (2005)